820 related articles for article (PubMed ID: 31278139)
1. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
McGonagle DG; McInnes IB; Kirkham BW; Sherlock J; Moots R
Ann Rheum Dis; 2019 Sep; 78(9):1167-1178. PubMed ID: 31278139
[TBL] [Abstract][Full Text] [Related]
2. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
Rosine N; Miceli-Richard C
Front Immunol; 2020; 11():553742. PubMed ID: 33488572
[TBL] [Abstract][Full Text] [Related]
3. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
Torgutalp M; Poddubnyy D
Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
[TBL] [Abstract][Full Text] [Related]
4. Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports.
Nagayasu A; Nawata M; Saito K; Tanaka Y
Mod Rheumatol Case Rep; 2020 Jul; 4(2):176-180. PubMed ID: 33086996
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
Braun J; Kiltz U; Baraliakos X
Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
Manasson J; Wallach DS; Guggino G; Stapylton M; Badri MH; Solomon G; Reddy SM; Coras R; Aksenov AA; Jones DR; Girija PV; Neimann AL; Heguy A; Segal LN; Dorrestein PC; Bonneau R; Guma M; Ciccia F; Ubeda C; Clemente JC; Scher JU
Arthritis Rheumatol; 2020 Apr; 72(4):645-657. PubMed ID: 31729183
[TBL] [Abstract][Full Text] [Related]
7. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
[TBL] [Abstract][Full Text] [Related]
8. Disease characteristics, pathogenesis, and treatment controversies of axial psoriatic arthritis.
Yousif P; Nahra V; Khan MA; Magrey M
Joint Bone Spine; 2024 Jan; 91(1):105625. PubMed ID: 37495073
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis.
Harrison SR; Marzo-Ortega H
Expert Rev Clin Immunol; 2021 Oct; 17(10):1059-1071. PubMed ID: 34407705
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
11. [Current treatment for spondyloarthritis: focus on netakimab. A review].
Karateev DE; Luchikhina EL
Ter Arkh; 2024 Jun; 96(5):543-550. PubMed ID: 38829817
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab: a promising therapeutic option in spondyloarthritis.
Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
[TBL] [Abstract][Full Text] [Related]
13. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
Sánchez-Rodríguez G; Puig L
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
[TBL] [Abstract][Full Text] [Related]
15. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
16. The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?
Siebert S; McGucken A; McInnes IB
Curr Opin Rheumatol; 2020 Jul; 32(4):349-356. PubMed ID: 32412997
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-17A Interweaves the Skeletal and Immune Systems.
Tang M; Lu L; Yu X
Front Immunol; 2020; 11():625034. PubMed ID: 33613566
[TBL] [Abstract][Full Text] [Related]
18. Psoriatic arthritis and spondyloarthritis assessment and management update.
Mease P
Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
[TBL] [Abstract][Full Text] [Related]
19. Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis.
Hammoura I; Fiechter RH; Bryant SH; Westmoreland S; Kingsbury G; Waegell W; Tas SW; Baeten DL; van de Sande MGH; van Tok MN; van Duivenvoorde LM
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055042
[TBL] [Abstract][Full Text] [Related]
20. No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors.
Zhang H; Jiang HL; Dai SM
Front Immunol; 2022; 13():818413. PubMed ID: 35222393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
